4 Active stocks to watch today 👀

This tiny stock could be on course for a major breakout after a recent FDA decision... Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Happy Monday! It's June 26th. I hope you had a great weekend! Let's get ready to trade! Markets 📈 Stocks stumbled last Friday and closed out the holiday-shortened trading week in the red. The Dow fell 0.6%, and the S&P 500 was close behind with a 0.7% loss. The Nasdaq underperformed with a 1.0% decline, and the small-cap Russell 2K sold off for 1.4%. Futures are edging lower in early-morning trading. S&P 500 contracts are currently carrying a 0.1% loss. Sponsored [A 100% Win Rate In 2022...]( 📈 The next 10 minutes could change your life. This reclusive millionaire hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. [Click here to see how he does it]( Premarket Highlights 🔎 ⚪ None Today's premarket is pretty quiet. No major market-moving news to report. No economy, only one earnings report. Should be a quiet session. What to Watch Today 👀 Trading Volumes We're getting into the meat of Summer, and that means a lot of investors are out soaking up the sun instead of making trades. This effect goes all the way up to Wall Street too, even the Smart Money tends to take a step back during the Summer months. Thin trading volumes could put a damper on the market's attempt at a rebound rally, so monitoring total market volumes could help you better anticipate the market's performance in the coming weeks. Major Earnings 💰 Carnival Corporation [CCL] ... AM Economy 🏗 None. Running Hot 🔥 Gainers - Digital Media Solutions [DMS] >> +56.0% - iMedia Brands [IMBI] >> +34.1% - Sqz Bio [SQZ] >> +25.7% - Eco Wave Power [WAVE] >> +18.5% Decliners - FibroGen [FGEN] >> (74.3%) - Avalo Therapeutics [AVTX] >> (64.9%) - Actelis Networks [ASNS] >> (23.1%) - Surgalign Holdings [SRGA] >> (20.5%) MoonLake Immunotherapeutics [MLTX] - Last Close: $25.88 MoonLake Immunotherapeutics is rallying on upbeat drug data. On Sunday, the biotech firm said a Phase 2 trial of Nanobody sonelokimab in patients with hidradenitis suppurativa met its primary endpoint. MoonLake says the data showed a "significantly greater proportion" of patients who received the therapy achieved clinical response. The drug's safety profil was consistent with previous studies. MLTX is one of this morning's top stocks, with a 57.7% gain. My Take: MLTX has performed surprisingly well this year, and this new drug could help it sustain its momentum. TRxADE Health [MEDS] - Last Close: $8.44 A newly announced merger deal is boosting shares of TRxADE Health. After Friday's close, the company announced t has agreed to a business combination with Superlatus. Under the terms of the deal, Superlatus will receive 3.8 million shares of MEDS, valued at $58.61 per share. Both companies' boards have unanimously approved the letter of intent. TRxADE also said it plans to divest its existing operating business and assets shortly after the merger. MEDS is up 67.3% on the merger report. My Take: MEDS has had an incredible run over the past few sessions. It could see more gains if it can keep the momentum rolling. Axcella Health [AXLA] - Last Close: $0.2514 An analyst upgrade is boosting shares of Axcella Health. Late Friday, Columbine Capital Service upgraded the company from 2 to 1. The company hasn't reported any other major news as of late, although it is coming off a sell off last week. AXLA is one of this morning's top stocks with a 19.3% gain. My Take: It looks like the analyst upgrade may have set off a rebound rally. AXLA performed poorly last week, but now it seems the sell off may have been overdone. INVO Bioscience [INVO] - Last Close: $0.1650 INVO Bio is up after a regulatory filing. After Friday's close, the biotech filed a Form S-1 regarding a planned offering of 6.2 million shares of common stock. The company says it's registering the shares for sale on behalf of its selling stockholders, and it will not receive proceeds from the sale. However, INVO could receive up to $3.6 million upon the cash exercise of each of the warrants included in the sale. INVO is up 83.3% in Monday's premarket, presumably in response to this filing. My Take: I'm not sure whether this news really explains this morning's rally, but it's all we have to go on at this point. INVO has performed very poorly since April, so a pullback could be in the cards. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](